Omalizumab in Severe and Refractory Solar Urticaria
Status:
Completed
Trial end date:
2015-09-29
Target enrollment:
Participant gender:
Summary
Solar urticaria is a rare disease, with a usual favourable outcome with photoprotection and
with anti H1 histamines. Nevertheless, some cases can be severe and refractory to this usual
treatment, leading to a large impact on quality of life. New treatment options are warranted.
The investigators aim to test the efficacy and the safety of omalizumab, an anti-IgE antibody
recently approved in chronic spontaneous urticaria, in this setting.